Chronotherapy in Glioblastoma: State of the art and future perspectives

Summary: Circadian rhythms regulate various processes in the human body, including drug metabolism. Chronotherapy optimizes treatment timing based on the circadian rhythm of the individual patient, such that the treatment efficacy is maximized, and adverse effects are minimized. It has been explored...

Full description

Bibliographic Details
Main Authors: Marina Petković, Melad Henis, Oliver Heese, Angela Relógio
Format: Article
Language:English
Published: Elsevier 2023-03-01
Series:EBioMedicine
Subjects:
Online Access:http://www.sciencedirect.com/science/article/pii/S235239642300035X
_version_ 1797905322726129664
author Marina Petković
Melad Henis
Oliver Heese
Angela Relógio
author_facet Marina Petković
Melad Henis
Oliver Heese
Angela Relógio
author_sort Marina Petković
collection DOAJ
description Summary: Circadian rhythms regulate various processes in the human body, including drug metabolism. Chronotherapy optimizes treatment timing based on the circadian rhythm of the individual patient, such that the treatment efficacy is maximized, and adverse effects are minimized. It has been explored in different cancers with varying conclusions. Glioblastoma multiforme (GBM) is the most aggressive type of brain tumour with a very dismal prognosis. In recent years, there has been very little success in designing successful therapies to fight this disease. Chronotherapy offers the opportunity to leverage existing treatments to extend patient survival and to increase their quality of life. Here, we discuss recent advances in using chronotherapy regimens in the treatment of GMB, such as radiotherapy, temozolomide (TMZ) and bortezomib, as well as discuss novel treatments with drugs of short half-life or circadian phase specific activity, and examine the therapeutic potential of new approaches that target elements of the core circadian clock.
first_indexed 2024-04-10T10:03:38Z
format Article
id doaj.art-57583d701a064e6a87a029d9dba4d17e
institution Directory Open Access Journal
issn 2352-3964
language English
last_indexed 2024-04-10T10:03:38Z
publishDate 2023-03-01
publisher Elsevier
record_format Article
series EBioMedicine
spelling doaj.art-57583d701a064e6a87a029d9dba4d17e2023-02-16T04:18:31ZengElsevierEBioMedicine2352-39642023-03-0189104470Chronotherapy in Glioblastoma: State of the art and future perspectivesMarina Petković0Melad Henis1Oliver Heese2Angela Relógio3Institute for Theoretical Biology (ITB), Charité—Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin and Berlin Institute of Health, Berlin 10117, GermanyInstitute for Systems Medicine and Faculty of Human Medicine, MSH Medical School Hamburg, Hamburg 20457, GermanyDepartment of Neurosurgery and Spinal Surgery, HELIOS Medical Center Schwerin, University Campus of MSH Medical School Hamburg, Hamburg 20457, GermanyInstitute for Theoretical Biology (ITB), Charité—Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin and Berlin Institute of Health, Berlin 10117, Germany; Institute for Systems Medicine and Faculty of Human Medicine, MSH Medical School Hamburg, Hamburg 20457, Germany; Medical Department of Hematology, Oncology, and Tumour Immunology, Molecular Cancer Research Center (MKFZ), Charité—Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin and Berlin Institute of Health, Berlin 10117, Germany; Corresponding author.Summary: Circadian rhythms regulate various processes in the human body, including drug metabolism. Chronotherapy optimizes treatment timing based on the circadian rhythm of the individual patient, such that the treatment efficacy is maximized, and adverse effects are minimized. It has been explored in different cancers with varying conclusions. Glioblastoma multiforme (GBM) is the most aggressive type of brain tumour with a very dismal prognosis. In recent years, there has been very little success in designing successful therapies to fight this disease. Chronotherapy offers the opportunity to leverage existing treatments to extend patient survival and to increase their quality of life. Here, we discuss recent advances in using chronotherapy regimens in the treatment of GMB, such as radiotherapy, temozolomide (TMZ) and bortezomib, as well as discuss novel treatments with drugs of short half-life or circadian phase specific activity, and examine the therapeutic potential of new approaches that target elements of the core circadian clock.http://www.sciencedirect.com/science/article/pii/S235239642300035XChronotherapyCircadian medicineCircadian rhythmGliomaGlioblastomaBrain cancer
spellingShingle Marina Petković
Melad Henis
Oliver Heese
Angela Relógio
Chronotherapy in Glioblastoma: State of the art and future perspectives
EBioMedicine
Chronotherapy
Circadian medicine
Circadian rhythm
Glioma
Glioblastoma
Brain cancer
title Chronotherapy in Glioblastoma: State of the art and future perspectives
title_full Chronotherapy in Glioblastoma: State of the art and future perspectives
title_fullStr Chronotherapy in Glioblastoma: State of the art and future perspectives
title_full_unstemmed Chronotherapy in Glioblastoma: State of the art and future perspectives
title_short Chronotherapy in Glioblastoma: State of the art and future perspectives
title_sort chronotherapy in glioblastoma state of the art and future perspectives
topic Chronotherapy
Circadian medicine
Circadian rhythm
Glioma
Glioblastoma
Brain cancer
url http://www.sciencedirect.com/science/article/pii/S235239642300035X
work_keys_str_mv AT marinapetkovic chronotherapyinglioblastomastateoftheartandfutureperspectives
AT meladhenis chronotherapyinglioblastomastateoftheartandfutureperspectives
AT oliverheese chronotherapyinglioblastomastateoftheartandfutureperspectives
AT angelarelogio chronotherapyinglioblastomastateoftheartandfutureperspectives